Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bide Pharmatech CoSHSE:688073 +5.56%85 EV-to-EBIT is 20.96 as of Sep. 16, 2026, which is 7% below its 10-year median of 22.42. GuruFocus rates SHSE:688073 with a GF Score™ of 85/100 and a GF Value™ of ¥64.94 (Fairly Valued). The stock has 4 warning signs investors should review. Among 682 Drug Manufacturers companies, Bide Pharmatech Co ranks worse than 61.29% on this metric.
Bide Pharmatech Co (SHSE:688073) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bide Pharmatech Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥3,817 Mil.
Bide Pharmatech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥236 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bide Pharmatech Co EV-to-EBIT Related Terms
Bide Pharmatech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bide Pharmatech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bide Pharmatech Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bide Pharmatech Co's EV-to-EBIT falls into.
Bide Pharmatech Co's current Enterprise Value is ¥4,944 Mil.
Bide Pharmatech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥236 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bide Pharmatech Co (SHSE:688073) has a EV-to-EBIT of 20.96 as of Sep. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bide Pharmatech Co and its competitors. This is near median its historical median of 22.42. Over the past decade, Bide Pharmatech Co's EV-to-EBIT has ranged from 12.69 to 44.27. According to the industry distribution chart, Bide Pharmatech Co ranks #418 out of 682 companies in the Drug Manufacturers industry, placing it in the top 61.3%.
Is Bide Pharmatech Co's EV-to-EBIT too high?
Bide Pharmatech Co's current EV-to-EBIT of 20.96 is near median its 10-year median of 22.42. Over the past 10 years, this metric has ranged from a low of 12.69 to a high of 44.27. The Drug Manufacturers industry median EV-to-EBIT is 16.04. Bide Pharmatech Co's value of 20.96 is 30.7% above this industry median. Based on the distribution chart, Bide Pharmatech Co ranks #418 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bide Pharmatech Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bide Pharmatech Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bide Pharmatech Co ranks #418 out of 682 companies for EV-to-EBIT. This places Bide Pharmatech Co in the lower half of its industry. The industry median EV-to-EBIT is 16.04. Bide Pharmatech Co's value of 20.96 is 30.7% above this benchmark. Historically, Bide Pharmatech Co's own EV-to-EBIT has ranged from 12.69 to 44.27 over the past decade. While the company's 10-year median is 22.42 vs. the industry median of 16.04, Bide Pharmatech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.04, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bide Pharmatech Co's current EV-to-EBIT of 20.96 is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bide Pharmatech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bide Pharmatech Co's current EV-to-EBIT is 20.96, which is near median its own 10-year median of 22.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bide Pharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, Bide Pharmatech Co (SHSE:688073) is currently considered Fairly Valued. The stock's GF Value™ is ¥64.94, compared to a current price of ¥64.15 — trading 1.2% below its estimated fair value. The current EV-to-EBIT is 20.96, which is near median its 10-year median of 22.42 and 30.7% above the Drug Manufacturers industry median of 16.04. Bide Pharmatech Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bide Pharmatech Co (SHSE:688073), the current EV-to-EBIT is 20.96 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bide Pharmatech Co (SHSE:688073) Overvalued in 2026?
Based on GuruFocus' analysis, Bide Pharmatech Co stock appears to be undervalued.
The current stock price of ¥64.15 is trading 1.2% below its estimated GF Value™ of ¥64.94.
GuruFocus considers Bide Pharmatech Co to be Fairly Valued.
Key valuation signals for SHSE:688073:
EV-to-EBIT: 20.96 (near median its 10-year median of 22.42)
GF Value™: ¥64.94 vs. price of ¥64.15 (1.2% below fair value)
Industry Position: 30.7% above the Drug Manufacturers median (#418 of 682)
No single metric tells the full story. See the SHSE:688073 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688073 has been successfully added to your 
